Skip to main content
Fig. 2 | Molecular Autism

Fig. 2

From: Characterization and structure-activity relationships of indenoisoquinoline-derived topoisomerase I inhibitors in unsilencing the dormant Ube3a gene associated with Angelman syndrome

Fig. 2

Western blot analysis demonstrating the capacity of indenoisoquinoline derivatives to increase paternal UBE3A-YFP at the protein level in cultured neurons from Ube3am+/pYFP mice. a Immunoblot and quantification of UBE3A-YFP levels normalized to actin in cultured neurons from wildtype (WT) or Ube3am+/pYFP mice treated with DMSO (0.1% vehicle control), topotecan (0.3 μM), indotecan (0.3 μM), or indimitecan (0.3 μM) (n = 3/group, *p < 0.05). b Immunoblots and quantification of UBE3A-YFP levels normalized to actin in cultured neurons from wildtype (WT) or Ube3am+/pYFP mice treated with DMSO (0.1% vehicle control), topotecan (0.3 μM), DB-IV-58 (0.3 μM), or DB-V-37 (0.3 μM) (n = 3/group, *p < 0.05)

Back to article page

Molecular Autism

ISSN: 2040-2392